About: Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
Creator	Meschi, Silvia Francesca, Colavita Licia, Bordi Alessandra, Brogi Caro, Di Concetta, Castilletti Daniele, Lapa Giulia, Matusali Giulia, Tesi Patrizia, Rosaria, Capobianchi Tommaso, Bandini
Source	MedRxiv
abstract	Serological assays for anti-SARS-CoV-2 antibodies are now of critical importance to support diagnosis, guide epidemiological intervention, and understand immune response to natural infection and vaccine administration. We developed and validated new anti-SARS-CoV-2 IgG, IgM and IgA ELISA tests (ENZY-WELL SARS-CoV-2 ELISA, DIESSE Diagnostica Senese S.p.a.) based on whole-virus antigens. We used a total of 553 serum samples including samples from COVID-19 suspected and confirmed cases, healthy donors, and patients positive for other infections or autoimmune conditions. Overall, the assays showed good concordance with the indirect immunofluorescence reference test in terms of sensitivity and specificity. Especially for IgG and IgA, we observed high sensitivity (92.5 and 93.6%, respectively); specificity was high (>96%) for all antibody types ELISAs. In addition, sensitivity was linked to the days from symptoms onset (DSO) due to the seroconversion window, and for ENZY-WELL SARS-CoV-2 IgG and IgA ELISAs resulted 100% in those samples collected after 10 and 12 DSO, respectively. The results showed that ENZY-WELL SARS-CoV-2 ELISAs may represent a valid option for both diagnostic and epidemiological purposes, covering all different antibody types developed in SARS-CoV-2 immune response.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.24.20111682
has license	medrxiv
sha1sum (hex)	b375a0aaad125a9931e918df472e270e23880e96
schema:url	https://doi.org/10.1101/2020.05.24.20111682
resource representing a document's title	Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
resource representing a document's body	covid:b375a0aaad125a9931e918df472e270e23880e96#body_text
is schema:about of	named entity 'specificity' named entity 'validated' named entity 'infections' named entity 'IgM' named entity 'epidemiological' named entity 'samples' named entity 'preprint' named entity 'samples' named entity 'INCLUDING' named entity 'CERTIFIED' named entity 'PEER REVIEW' named entity 'INFECTIONS' named entity 'RESPONSE TO' named entity 'DIFFERENT' named entity '100%' named entity 'WINDOW' named entity 'AVAILABLE' named entity 'TESTS' named entity 'AUTHOR' named entity 'peer review' named entity 'IgA' named entity 'samples' named entity 'tests' named entity 'Evaluation' named entity 'antibody' named entity 'preprint' named entity 'sensitivity and specificity' named entity 'indirect immunofluorescence' named entity 'infection' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'DIESSE' named entity 'ELISAs' named entity 'DSO' named entity 'medRxiv' named entity 'IgG' named entity 'IgM' named entity 'IgA' named entity 'SARS' named entity 'diagnosis' named entity 'SARS-CoV-2' named entity 'RT-PCR test' named entity 'antibody testing' named entity 'CC-BY-NC-ND 4.0' named entity 'Siena' named entity 'preprint' named entity 'preprint' named entity 'ELISAs' named entity 'coronavirus disease 2019' named entity 'antibody' named entity 'IgG' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'IgG' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'IgG' named entity 'IgG antibodies' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'rapid tests' named entity 'virus' named entity 'antibody testing' named entity 'cross-reactivity' named entity 'IgA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software